After identifying the two most potent inhibitors, their potential to cause PARP-1 trapping and their cytotoxicity was investigated in CRC cells proficient or deficient for PARP-1, BRCA2, and ATR and compared to human colonic epithelial cells (HCEC). This evidence concerns the gene BRCA2 and colorectal carcinoma.